Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5851464 | 0.85 | HDAC6 (0.43) | HDAC6HDAC1HDAC10CNR2HDAC3 | |
| SCHEMBL5851593 | 0.82 | HDAC6 (0.57) | HDAC6HDAC1HDAC10CNR2HDAC3 | |
| SCHEMBL5850826 | 0.82 | HDAC6 (0.59) | HDAC6HDAC1HDAC10CNR2HDAC3 | |
| SCHEMBL5851549 | 0.82 | HDAC6 (0.46) | HDAC6HDAC1HDAC10CNR2HDAC3 | |
| SCHEMBL5850855 | 0.78 | HDAC6 (0.57) | HDAC6HDAC1HDAC10CNR2HDAC3 | |
| SCHEMBL2943380 | 0.78 | MAOB (0.40) | HDAC6HDAC1HDAC10HDAC3HDAC4 | |
| SCHEMBL5849208 | 0.78 | HDAC6 (0.46) | HDAC6HDAC1HDAC10CNR2HDAC3 | |
| SCHEMBL6220738 | 0.76 | CNR2 (0.45) | HDAC6HDAC1HDAC10CNR2MEN1 | |
| SCHEMBL5849331 | 0.74 | CNR2 (0.42) | CNR2TP53ALDH1A1CFDMAPT | |
| SCHEMBL5849849 | 0.73 | TP53 (0.41) | CNR2TP53MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001912-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | claimed |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | claimed |
| US-7138408-B2 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060122211-A1 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| US-7001912-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1590349-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2004067531-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122211-A1 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | POLB, POLA1, TYMP | HDAC6 1457/4885HDAC1 99/4885HDAC10 382/4885 |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | POLB, APOBEC3C, IDH3A | HDAC6 1168/4885HDAC1 74/4885HDAC10 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.